| Etanercept cohort (N = 2725) | Biologic-naïve cohort (N = 1517) | p†|
---|---|---|---|
Gender, female | 1829 (67.1) | 1023 (67.4) | 0.8 |
Age at onset (years) | 7.9 ± 4.7 | 7.7 ± 4.6 | 0.18 |
Age at baseline (years) | 12.1 ± 4.4 | 9.8 ± 4.8 | < 0.0001* |
Disease duration (years) | 4.1 ± 3.7 | 2.1 ± 2.8 | < 0.0001* |
JIA category | |||
 Systemic JIA | 146 (5.3) | 58 (3.8) | 0.025* |
 RF-negative polyarthritis | 904 (33.1) | 415 (27.3) | < 0.0001* |
 RF-positive polyarthritis | 223 (8.1) | 52 (3.4) | < 0.0001* |
 Persistent oligoarthritis | 120 (4.4) | 390 (25.7) | < 0.0001* |
 Extended oligoarthritis | 570 (20.9) | 204 (13.4) | < 0.0001* |
 ERA | 486 (17.8) | 213 (14.0) | 0.001* |
 PsA | 191 (7.0) | 138 (9.0) | 0.017* |
 Unclassified JIA | 85 (3.1) | 47 (3.0) | 1.0 |
ANA | 1290 (47.3) | 725 (47.8) | 0.8 |
HLA-B27 | 643 (23.6) | 265 (17.5) | < 0.0001* |
Pretreatment at baseline | |||
 NSAIDs | 2478 (90.9) | 1329 (87.6) | 0.0007* |
 Systemic steroids | 1434 (52.6) | 357 (23.5) | < 0.0001* |
 MTX | 2358 (86.5) | 0 (0) | < 0.0001* |
 Biologics | 114 (4.2) | 0 (0) | < 0.0001* |
 Other DMARDs | 1232 (45.2) | 149 (9.8) | < 0.0001* |
  SFZ | 415 (15.2) | 67 (4.4) | < 0.0001* |
  HCQ | 228 (8.4) | 53 (3.5) | < 0.0001* |
  AZA | 237 (8.7) | 14 (0.9) | < 0.0001* |
  LEF | 85 (3.1) | 6 (0.4) | < 0.0001* |
  CSA | 140 (5.1) | 8 (0.5) | < 0.0001* |
  Chlorambucil | 19 (0.7) | 0 (0) | 0.0004* |
  Cyclophosphamide | 10 (0.4) | 0 (0) | 0.0175* |
  Gold salts | 36 (1.3) | 0 (0) | < 0.0001* |
  Immunoglobulins | 48 (1.8) | 1 (0.1) | < 0.0001* |
  MMF | 14 (0.5) | 0 (0) | 0.0034* |
Concomitant treatment at baseline | |||
 NSAIDs | 2158 (79.2) | 360 (23.7) | 0.0001* |
 Systemic steroids | 974 (35.7) | 1394 (91.9) | 0.0001* |
 MTX | 1867 (68.5) | 1517 (100.0) | < 0.0001* |
 Other DMARDs | |||
  SFZ | 145 (5.3) | 36 (2.4) | 0.0001* |
  HCQ | 37 (1.4) | 14 (0.9) | 0.24 |
  AZA | 80 (2.9) | 4 (0.3) | 0.0001* |
  LEF | 59 (2.2) | 1 (0.1) | 0.0001* |
  CSA | 57 (2.1) | 2 (0.1) | 0.0001* |
Disease activity parameters at baseline | |||
 Active joints | 6.7 ± 8.1 | 5.8 ± 7.6 | 0.0004* |
 Swollen joints | 5.3 ± 7.4 | 4.8 ± 6.8 | 0.03* |
 Tender joints | 6.5 ± 8.4 | 5.8 ± 7.8 | 0.007* |
 PhysVAS | 52.2 ± 32.3 | 47.2 ± 25.9 | 0.0001* |
 PatVAS | 43.7 ± 27.4 | 39.0 ± 26.0 | 0.0001* |
 Joints with LOM | 7.4 ± 8.9 | 5.7 ± 7.6 | 0.0001* |
 CHAQ-DI | 0.7 ± 0.6 | 0.6 ± 0.6 | 0.0001* |
 ESR (mm/h) | 23.5 ± 23.4 | 24.2 ± 23.0 | 0.35 |
 CRP (mg/L) | 16.8 ± 32.7 | 13.9 ± 27.9 | 0.004* |
 JADAS10 | 15.3 ± 7.5 | 13.9 ± 7.1 | 0.0001* |